Analysts expect Nervgen Pharma Corp. to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Nervgen Pharma Corp. to report earnings per share of -0.10 for Q3 26, against a range of -0.10 to -0.10. The most recent reported quarter, Q2 26, came in at -0.27, a 350.0% miss against the -0.06 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.05 | -0.10 | -0.04 | -0.09 | -0.04 | -0.26 | -0.01 | -0.27 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.05 | -0.06 | -0.06 | -0.05 | -0.06 | -0.05 | -0.07 | -0.05 | -0.10 | -0.10 | -0.09 | -0.09 | -0.06 | -0.12 | -0.07 | -0.13 | ||||||||||
| Low Estimate | -0.05 | -0.06 | -0.06 | -0.05 | -0.06 | -0.07 | -0.07 | -0.07 | -0.10 | -0.12 | -0.09 | -0.11 | -0.06 | -0.14 | -0.07 | -0.15 | ||||||||||
| Consensus Estimate | -0.05 | -0.06 | -0.06 | -0.05 | -0.06 | -0.06 | -0.07 | -0.06 | -0.10 | -0.11 | -0.09 | -0.10 | -0.06 | -0.13 | -0.07 | -0.14 |